The rise and fall of rosiglitazone
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This editorial refers to ‘Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial’†, by M. Komajda et al. on page 824 Komajda et al. have described the increased incidence of congestive heart failure (CHF) in patients treated with rosiglitazone in the RECORD Trial (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes).1 This study is the latest chapter in the tortured saga of rosiglitazone, a drug that was once the largest selling diabetes therapy in the world.2 The rise and fall of rosiglitazone raises critical scientific and ethical questions about drug development and marketing, with profound consequences, including the recent decision by US regulatory authorities to require cardiovascular outcome studies for all new diabetes drugs.3 Rosiglitazone and related thiazolidindiones (TZDs) are modulators of nuclear receptor proteins known as peroxisome proliferator-activated receptors (PPARs) that function as transcription factors regulating expression of genes. Of the many subclasses of PPAR modulators, two types have been marketed, PPARα agents, such as fenofibrate, that affect lipid metabolism, and PPARγ agents, such as rosiglitazone, that act as insulin sensitizers. One marketed TZD, pioglitazone, is considered a dual PPAR agonist, with modest α effects and strong γ effects. PPARs influence a large number of genes, perhaps 100 or more, most of which have unknown biological effects. Accordingly, the effects of these agents are unpredictable and can result in unusual toxicities. Indeed, during the past decade, >50 PPAR agonists have failed during clinical development, some due to cardiotoxicity,4 although few publications have detailed the precise toxicity encountered. One agent, muraglitazar, was recommended for approval by a US Food and Drug Administration (FDA) advisory panel, but ultimately not approved after a meta-analysis of clinical trials obtained from FDA documents revealed an approximate doubling of adverse cardiovascular outcomes.5 In 1998, the only marketed TZD was troglitazone, a drug that had come under intense scrutiny for rare, but potentially fatal hepatotoxicity. The FDA appeared eager to approve a ‘safer’ alternative to troglitazone. Since both rosiglitazone and pioglitazone appeared to lack hepatotoxicity, the FDA moved swiftly to approve these agents. The rosiglitazone development programme was small, although typical of diabetes drugs in that era, consisting of five trials involving 2902 patients, mostly short-term (26 week) glycaemic control studies.6 In three pivotal studies (011, 024, and 020), rosiglitazone substantially increased LDL cholesterol (LDL-C), averaging 24, 20, and 13%, respectively. Of greater concern, in all five trials, ischaemic cardiovascular events occurred in 36/2902 patients receiving rosiglitazone and 10/1452 patients receiving comparators, a relative risk of 1.80 (P = NS), with confidence intervals not reported by the FDA statistician.6 There was no evidence of serious hepatotoxicity. On 22 May 1999, an FDA advisory panel recommended approval of rosiglitazone, and 3 days later the Agency sent an approval letter (Table 1). Two months later, the FDA approved pioglitazone. With two available alternatives, in March 2000, the FDA ordered the removal of troglitazone from the market. In the rosiglitazone review, the FDA officer expressed concern about ‘EKG changes, chest pain, etc., even if not statistically different from comparators’ and commented that ‘based upon animal findings of cardiomegaly, and edema in clinical trials, RSG should be used with caution in patients with heart failure’.6 The reviewer further opined that ‘undesirable’ changes in weight and lipids were a ‘cause for concern’. He wrote that ‘heart disease due to atherosclerosis is a major cause of morbidity and mortality in patients with Type 2 diabetes, and it cannot be assumed that RSG will decrease the risk’. Finally, the reviewer recommended that a post-marketing study designed to address these issues should be a condition for approval. Timeline: the rise and fall of rosiglitazone ADA, American Diabetes Association; ADOPT, A Diabetes Outcome Progression Trial; CHF, congestive heart failure; CV, cardiovascular; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication; EASD, European Association for the Study of Diabetes; FDA, Food and Drug Administration; GSK, Glaxo Smith Kline, RECORD, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes. Timeline: the rise and fall of rosiglitazone ADA, American Diabetes Association; ADOPT, A Diabetes Outcome Progression Trial; CHF, congestive heart failure; CV, cardiovascular; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication; EASD, European Association for the Study of Diabetes; FDA, Food and Drug Administration; GSK, Glaxo Smith Kline, RECORD, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation o
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 2×
“74).(18) GSK, forewarned by the leak of the manuscript, hastily arranged partially to unblind the ongoing RECORD Trial, which enabled publication online only 16 days after the rosiglitazone meta-analysis.”
BackgroundSelf-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Komajda, M., McMurray, J. J. V., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P., & Home, P. D. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp604 · Cited by 234 · cited 1×
“have described the increased incidence of congestive heart failure (CHF) in patients treated with rosiglitazone in the RECORD Trial (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes).(1) This study is the latest chapter in the tortured saga of rosiglitazone, a drug that was once the…”
BackgroundLincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Self-citation
Cited by
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Self-citationThiazolidinediones as antidiabetic agents: A critical review
Nanjan, M. J., Mohammed, M., Prashantha Kumar, B. R., & Chandrasekar, M. J. N. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.02.009 · Cited by 316
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Gilbert, R. E., & Krum, H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61402-1 · Cited by 293
Alomar, M., Tawfiq, A. M., Hassan, N., & Palaian, S. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620938595 · Cited by 272
Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
Metadata
- Authors
- Nissen, S. E.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02-12
- Volume
- 31
- Issue
- 7
- Pages
- 773-776
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2140161503
- Cited by
- 90
- References
- 7
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The rise and fall of rosiglitazone. https://app.cochat.ai/papers/10.1093/eurheartj/ehq016
- The paper
- Nissen, S. E. (2010). The rise and fall of rosiglitazone. European Heart Journal. https://doi.org/10.1093/eurheartj/ehq016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.